Full metadata record
DC FieldValueLanguage
dc.contributor.authorKROLICKI LESZEKen_GB
dc.contributor.authorBRUCHERTSEIFER FRANKen_GB
dc.contributor.authorKUNIKOWSKA JOLANTAen_GB
dc.contributor.authorKOZIARA Hen_GB
dc.contributor.authorKROLICKI Ben_GB
dc.contributor.authorJAKUCINSKI Men_GB
dc.contributor.authorPAWLAK DARIUSZen_GB
dc.contributor.authorAPOSTOLIDIS CHRISTOSen_GB
dc.contributor.authorROLA Ren_GB
dc.contributor.authorMERLO A.en_GB
dc.contributor.authorMORGENSTERN ALFREDen_GB
dc.date.accessioned2017-08-03T00:32:44Z-
dc.date.available2017-08-01en_GB
dc.date.available2017-08-03T00:32:44Z-
dc.date.created2017-07-03en_GB
dc.date.issued2017en_GB
dc.date.submitted2017-03-13en_GB
dc.identifier.urihttp://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/en_GB
dc.identifier.urihttp://publications.jrc.ec.europa.eu/repository/handle/JRC106153-
dc.description.abstractGlioblastoma multiforme (GBM), the most common primary brain tumor in adults, has a very poor prognosis with a median overall survival of 14.6 months despite of aggressive therapy. Targeted alpha therapy (TAT) with the short range, high LET alpha emitters 213Bi and 225Ac offers the potential for selective irradiation of tumors and minimizing damage to adjacent regions of the brain. The low-molecular weight peptide carrier substance P is targeting NK 1 receptors, which are consistently over-expressed on GBM cells. We report our clinical experience with 213Bi-DOTA-Substance P (213Bi-SP) and 225Ac-DOTAGA-Substance P (225Ac-SP) in patients with recurrent GBM.en_GB
dc.description.sponsorshipJRC.G.I.5-Advanced Nuclear Knowledgeen_GB
dc.format.mediumPrinteden_GB
dc.languageENGen_GB
dc.publisherEuropean Commission - Joint Research Centreen_GB
dc.relation.ispartofseriesJRC106153en_GB
dc.titleTargeted alpha therapy of glioblastoma multiforme: clinical experience with 213Bi- and 225Ac-Substance Pen_GB
dc.typeArticles in periodicals and booksen_GB
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.